The authors of “PSMA PET Tumor–to–Salivary Gland Ratio to Predict Response to [177Lu]PSMA Radioligand Therapy: An International Multicenter Retrospective Study” include Masatoshi Hotta, Andrei Gafita, Vinshu Murthy, Matthias R. Benz, Ida Sonni, Johannes Czernin, and Jeremie Calais, Ahmanson Translational Theranostics Division, UCLA, Los Angeles, California; Irene A. Burger, Department of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland; Matthias Eiber, Department of Nuclear Medicine, Technical University of Munich, Munich, Germany; Louise Emmett, Department of Theranostics and Nuclear Medicine, St. Vincent’s Hospital, Sydney, New South Wales, Australia; Andrea Farolfi, Ahmanson Translational Theranostics Division, UCLA, Los Angeles, California, and Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Wolfgang P. Fendler and Manuel M. Weber, Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium-University Hospital Essen, Essen, Germany; Michael S. Hofman, Prostate Cancer Theranostics and Imaging Centre of Excellence, Molecular Imaging Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia; Thomas A. Hope, Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California; and Clemens Kratochwil, Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.

Back to HCB News

Molecular Imaging Homepage